相关实验视频

Updated: Sep 9, 2025

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation

Published on: September 29, 2019

在败血症和败血性休克中使用多素B的临床应用

Fiorenza Ferrari^1,2, Yaroslava Longhitano³, Antonio Voza^4,5

¹International Renal Research Institute of Vicenza (IRRIV), Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy.

Journal of intensive care medicine

|September 1, 2025

概括

用于治疗败血症和败血性休克的药物,聚氨酸B血 perfusion (PMX- HA) 可去除内毒素. 根据患者的严重程度和内毒素水平进行个性化治疗对于最佳结果至关重要.

科学领域:

危急护理医学
免疫学
肝脏病学

背景情况:

败血症和败血性休克 (SS) 是危及生命的疾病,涉及免疫失调和多器官衰竭 (MOF).
目前针对个体调解者的治疗方法取得了有限的成功.
通过消除内毒素来调节免疫反应的新方法是用多素B (PMX) 进行血吸 (HA).

研究的目的:

审查20年来PMX输血 (PMX- HA) 在患有败血症的重症患者的使用情况,重点是内毒性败血性休克.
探索PMX-HA降低炎症媒介和调节免疫细胞活动的机制.
确定PMX- HA治疗的最佳患者群体和治疗策略.

主要方法:

在过去二十年中对重症患者进行的PMX-HA研究的综述.
分析PMX-HA对内毒素水平,炎症标志物和免疫细胞功能的影响.
检查患者异质性及其对治疗结果的影响.

主要成果:

PMX-HA有效地消除内毒素,减少炎症媒介,并调节免疫细胞功能.
治疗的成功是可变的,受患者异质性,疾病严重程度和内毒素负担的影响.
通过内毒素活性 (EAA),SOFA分数和乳酸盐水平进行分层对于患者的选择至关重要.

结论:

对于败血症和败血性休克来说,PMX-HA是一种有前途的治疗方法,特别是在具有高内毒素活性和严重器官功能障碍的患者中.
对PMX-HA进行个性化治疗,包括定制时间,剂量和持续时间,对于优化临床结果至关重要.
未来的研究应该完善患者选择标准,并确定PMX-HA的最佳治疗方案.

关键词:

急性损伤细胞因子风暴内毒性冲击身体外血液净化血液吸收免疫调节聚氨酸 b 感染性疾病败血症冲击

更多相关视频

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

相关概念视频

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Acute Pyelonephritis II: Diagnostic Studies and Management

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...